In Section C, individuals will acquire ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Members will get treatment until finally disorder progression or the participants are unable to tolerate the study drugs. Celastrol was identified as a Myb inhibitor that suppressed C/EBPβ action and repressed https://how-does-abbv-744-work-in36802.oblogation.com/31344542/clinical-trial-recruitment-for-abbv-744-study-fundamentals-explained